SCHEDULE 13G/A: Corvus Pharmaceuticals Insider Dr. Richard Miller Boosts Stake to 7.7% in Latest SEC Filing

Dr. Richard A. Miller, a key figure at Corvus Pharmaceuticals, Inc., has increased his beneficial ownership in the company to 7.7% as of December 31, 2024, according to a recent Schedule 13G/A filing.

Summary

• Dr. Richard A. Miller, a reporting person, beneficially owns an aggregate of 5,220,368 shares of Corvus Pharmaceuticals, Inc. common stock, representing 7.7% of the class.
• This ownership includes 1,765,737 shares held directly by the Miller-Horning Family Trust, 559,073 shares underlying warrants exercisable within 60 days, and 2,895,558 shares underlying stock options vested or vesting within 60 days.
• The Miller-Horning Family Trust, with Dr. Miller and Dr. Sandra J. Horning as trustees, beneficially owns 1,765,737 shares, representing 2.7% of the class.
• Dr. Sandra J. Horning also beneficially owns 1,765,737 shares, representing 2.7% of the class, primarily through shared voting and dispositive power over the Miller-Horning Trust's holdings.
• The percentages are calculated based on 64,257,251 shares of Common Stock outstanding as of November 12, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q, and assume the exercise of warrants and stock options held by each respective reporting person.
• This filing is an Amendment No. 9 to a Schedule 13G, indicating an update to previously reported beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment beyond the fact of insider holdings.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an insider (Dr. Richard A. Miller, likely a founder or executive given the name and substantial holdings) in a publicly traded biotechnology company. Such disclosures provide transparency regarding insider confidence and alignment with shareholder interests, which is a common practice across all industries, including pharmaceuticals.

Related Party Transactions

• The filing discloses beneficial ownership by Dr. Richard A. Miller and Dr. Sandra J. Horning, who are trustees of the Miller-Horning Family Trust, indicating a related party holding structure.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant insider ownership, which can be viewed as a sign of confidence in the company's future by its leadership.

Key Dates

Keywords

Corvus Pharmaceuticals, Richard A. Miller, Sandra J. Horning, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Insider Ownership, Biotechnology, Pharmaceuticals